We are happy to direct you to the newest edition of the EMA monthly newsletter, the June 2022 (159) edition. As usual, it contains the list of new drugs approved in the areas of antivirals, cancer, diabetes, gastrointestinal system, gynecology, hematology, hormone and immune systems, metabolic disorders, musculoskeletal system, nephrology, nervous system, rheumatology, urology, and vaccines.
It contains reports of the Scientific Committees and Working Parties meetings, and new guidelines.
It also contains a special section regarding a COVID-19 vaccines safety update for Comirnaty (BioNTech), Jcovden (Janssen-Cilag), Nuvaxovid (Novavax), Spikevax (Moderna Biotech) and Vaxzevria (AstraZeneca).
You can access the full newsletter here.
Disclaimers
- The material in these reviews is from various public open access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
